外源抗原升调增强了抗体的作用 针对白血病的纳米化疗
Shujing Yue1, Jingnan An2, Yifan Zhang1
1Biomedical Polymers Laboratory, College of Chemistry, Chemical Engineering and Materials Science, and State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou, 215123, P. R. China.
Advanced materials (Deerfield Beach, Fla.)
|June 15, 2023
概括
这项研究表明,全转网红酸 (ATRA) 可以在白血病细胞上增加CD38,从而实现向纳米化疗. 这种组合疗法在急性髓性白血病 (AML) 模型中显著改善了生存率.
科学领域:
- 在瘤学瘤学.
- 纳米医学是一种纳米医学.
- 免疫治疗是一种免疫疗法.
背景情况:
- 急性髓性白血病 (AML) 的死亡率很高,治疗策略有限.
- 白血病细胞上缺乏特定的表面抗原,阻碍了向治疗和基于细胞的治疗.
- CD38是一种表面抗原,具有作为治疗点的潜力.
研究的目的:
- 为了研究全转网红酸 (ATRA) 在白血病细胞上调调高CD38表达的潜力.
- 开发和评估使用daratumumab抗体导向的聚合体温克里斯硫酸盐 (DPV) 与ATRA结合的向纳米化疗.
- 在临床前AML模型中评估这种综合方法的有效性.
主要方法:
- 给出异源的全转网红酸 (ATRA) 诱导白血病细胞的CD38表达.
- 开发达拉图穆马布抗体导向的聚合体温克里斯硫酸盐 (DPV) 用于向的输送.
- 用ATRA和DPV组合疗法治疗表达CD38低的AML正型小鼠模型.
主要成果:
- 治疗ATRA导致了对白血病细胞的CD38的选择性和暂时上调,高达20倍.
- ATRA和DPV组合策略有效地根除了循环中的白血病细胞,并减少了对骨髓和器官的入侵.
- 观察到显著的生存益处,20-40%的治疗小鼠实现了无白血病状态.
结论:
- 通过ATRA对外的CD38上调调节可以提高向纳米化疗的疗效.
- CD38上调和抗体导向纳米疗法的组合为AML提供了一种新且强大的向治疗方法.
- 这种方法有望克服治疗耐药性并改善急性髓性白血病的结果.
相关概念视频
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
01:27Tumor Immunotherapy
575
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
575